Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (121-130 of 206) with videos related to

Pageof 21
Sort By:
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2002
Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcomaJasjit Gill, Dimitra Bourboulia, John Wilkinson, et al.
AIDS (London, England)|June 23, 2006
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersAlan Winston, David Back, Carl Fletcher, et al.
Controlled Clinical Trials|July 17, 2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA TrialTassos C Kyriakides, Abdel Babiker, Joel Singer, et al.
AIDS (London, England)|December 15, 2010
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected populationMark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal diseaseMelanie Hart, Alan Steel, Sally A Clark, et al.
Journal of Immune Based Therapies and Vaccines|April 13, 2007
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapyGareth Ad Hardy, Nesrina Imami, Mark R Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2012
Biomarkers to monitor safety in people on art and risk of mortalityLoveleen Bansi, Brian Gazzard, Frank Post, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith, Schlomo Staszewski, Caroline A Sabin, et al.
Pageof 21

Showing results (121-130 of 206) with videos related to

Sort By:
Pageof 21
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2002
Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcomaJasjit Gill, Dimitra Bourboulia, John Wilkinson, et al.
AIDS (London, England)|June 23, 2006
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersAlan Winston, David Back, Carl Fletcher, et al.
Controlled Clinical Trials|July 17, 2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA TrialTassos C Kyriakides, Abdel Babiker, Joel Singer, et al.
AIDS (London, England)|December 15, 2010
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected populationMark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal diseaseMelanie Hart, Alan Steel, Sally A Clark, et al.
Journal of Immune Based Therapies and Vaccines|April 13, 2007
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapyGareth Ad Hardy, Nesrina Imami, Mark R Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2012
Biomarkers to monitor safety in people on art and risk of mortalityLoveleen Bansi, Brian Gazzard, Frank Post, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith, Schlomo Staszewski, Caroline A Sabin, et al.
Pageof 21